Journal of Child and Adolescent Psychopharmacology

Article	Citations
Letter to the Editor: Skin-Testing for Clones—Pediatric Obsessive Compulsive Disorder with Misidentification Syndrome	27
Program Evaluation to Aid Choice of Aripiprazole or Risperidone for Hospitalized Adolescents with Cannabis Use Disorder and Psychosis	26
Acknowledgment of Reviewers 2023	26
Description, Implementation, and Efficacy of the Comprehensive Behavioral Intervention for Tics as First-Line Treatment for Tourette and Other Tic Disorders	23
Reducing Psychotropic Medication Use in Foster-Care Children with a Personalized Medication Review	21
Pharmacogenetics in Child and Adolescent Psychiatry: Background and Evidence-Based Clinical Applications	19
Letter: Mirtazapine-Associated Hyperkinetic Movements in a 17-Year-Old with Autism Spectrum Disorder and Chronic Catatonia: A Case Report	19
Pharmacological Treatment of Tourette Disorder in Children	19
Navigating Pharmacological Treatment in an Adolescent with New Onset Psychosis: Clinical, Pharmacological, and Cultural Challenges	17
Letter: Preliminary Observations from a Randomized, Open-Label Trial of Loperamide as Adjunctive Treatment for Social Deficits in Autism Spectrum Disorder	15
Monitoring of Adverse Drug Reaction-Related Parameters in Children, Youth, and Young Adults Prescribed Antipsychotic Drugs by General Practitioners	15
From the Editor-in-Chief's Desk: Reflecting on Our Past and Future	15
Effects of Long-Term Sertraline Use on Pediatric Growth and Development: The Sertraline Pediatric Registry for The Evaluation of Safety (SPRITES)	15
Incidence of Neuroleptic Malignant Syndrome During Antipsychotic Treatment in Children and Youth: A National Cohort Study	14
From the Editor's Desk: Progress and Challenges for Psychiatric Phenotypes in Youth	13
A Double-Blind Placebo-Controlled Pilot Study of Topiramate in Manic Adolescents Treated with Olanzapine	13
Letter: Improving Outcomes in Level 3 Autism after Treating Co-Occurring ADHD	12
Response to Plöderl et al. re: “A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder”	12
From the Editor-in-Chief’s Desk: Long-Acting Injectable Antipsychotics	11
Psychotropic Medication Prescribing: Youth in Foster Care Compared with Other Medicaid Enrollees	11
Placebo Response on Attention-Deficit/Hyperactivity Disorder Ratings: Application to Multimodal Treatment Study of Attention-Deficit/Hyperactivity Disorder 3-Month Outcomes	11
Letter to the Editor: Transition to In-Person School After Remote Learning—Mental Health Concerns in Youth with Developmental Disabilities	11
Short-Term Vision-Related Ocular Side Effects of Treatment with Dexmethylphenidate for Attention-Deficit/Hyperactivity Disorder	11
A Mobile Application Adjunct to Augment Cognitive–Behavioral Group Therapy for Adolescents with Social Anxiety: Feasibility and Acceptability Results from the Wiring Adolescents with Social Anxiety vi	10
Pharmacological Interventions for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents with Tourette Disorder: A Systematic Review and Network Meta-Analysis	10

Reported Side or Adverse Effects Associated with Medication Nonadherence Among Adolescents and Young Adults with Attention-Deficit/Hyperactivity Disorder	9
Combined Topiramate and Metformin Pharmacotherapy for Second-Generation Antipsychotic-Induced Weight Gain in Pediatric Bipolar Disorder and Aggression	8
Pediatric Neuropsychiatric Syndromes: Updates on COVID-19 Infection and Vaccination	8
Determining Clinically Meaningful Improvement in Children and Adolescents with Tourette Syndrome Receiving Pharmacotherapy	8
A Counting Stroop Functional Magnetic Resonance Imaging Study on the Effects of ORADUR-Methylphenidate in Drug-Naive Children with Attention-Deficit/Hyperactivity Disorder	8
Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study	8
Psychedelic Treatments in Adolescent Psychopharmacology: Considering Safety, Ethics, and Scientific Rigor	8
Association of Coexisting Conditions, Attention-Deficit/Hyperactivity Disorder Medication Choice, and Likelihood of Improvement in Preschool-Age Children: A Developmental Behavioral Pediatrics Researc	8
Letter: Integrating Insights on Ketamine Efficacy and the Risk for Polydrug Use in Adolescents with Depression	8
From the Editor-in-Chief’s Desk: Maximizing Adherence, Digital Platforms, and Early Response for Precision Pediatric Psychopharmacology	7
Can Neurocognitive Outcomes Assist Measurement-Based Care for Children with Attention-Deficit/Hyperactivity Disorder? A Systematic Review and Meta-Analyses of the Relationships Among the Changes in Ne	7
Fluoxetine-Induced Serum Sickness-Like Reaction in an Adolescent with Obsessive Compulsive Disorder and Diabetes	7
Psychiatric Polygenic Risk Scores and Week-by-Week Symptomatic Status in Youth with Bipolar Disorder: An Exploratory Study	7
Letter to the Editor: Suicide Risk Screening Practices in Youth with Developmental Disabilities	7
Ketamine and Transcranial Magnetic Stimulation in an Adolescent with Treatment-Resistant Depression	7
The Curious Case of Therapist Self-Disclosure During Pharmacotherapy Visits in an Autism Center	7
Changes in Psychiatric Medication Use During the COVID-19 Pandemic in a Pediatric Long-Term Care Facility	7
Letter to the Editor: The Impact of the COVID-19 Pandemic on the Mental Health of Youth with Developmental Disabilities	7
Rational Psychopharmacological and Psychotherapeutic Treatment of a 14-Year-Old Female with Functional Neurological Symptoms Disorder and Depression	7
A Preclinical Study of Standard Versus Accelerated Transcranial Magnetic Stimulation for Depression in Adolescents	6
Long-Term Improvement and Safety of Aripiprazole for Irritability and Adaptive Function in Asian Children and Adolescents with Autistic Disorder: A 52-Week, Multinational, Multicenter, Open-Label Stud	6
The Safety and Clinical Effects of Amisulpride in Children and Adolescents with Psychiatric Disorders: A Case Series	6
Long-Acting Injectable Antipsychotics in Adolescents with Bipolar Disorder	6
From the Editor-in-Chief's Desk	6
Vascular Endothelial Growth Factor Polymorphism rs699947 Is Associated with Neurostructural Phenotypes in Youth with Bipolar Disorder	6
Examining Whether Genetic Variants Moderate the Skeletal Effects of Selective Serotonin Reuptake Inhibitors in Older Adolescents and Young Adults	6
Erratum to: Assessing the Predictive Utility of Quantitative Electroencephalography Coherence in Adolescent Major Depressive Disorder: A Machine Learning Approach	6
Correction to: A Predictive Biomarker Model Using Quantitative Electroencephalography in Adolescent Major Depressive Disorder, by McVoy, et al. J Child Adolesc Psychopharmacol 2022;32(9)	6
Relative Age and the Use of Second-Generation Antipsychotics from 7 to 17 Years of Age: A Population-Based Register Study	6
Response to Chadi A. Calarge re: “Effects of Long-Term Sertraline Use on Pediatric Growth and Development: The Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES)”	6
Letter: Collaborating with Applied Behavior Analysis Teams to Optimize Telehealth Pharmacologic Management of Catatonia in Nonverbal Youth with Autism Spectrum Disorder	6
From the Editor-in-Chief’s Desk: Gratitude for Mentors and Colleagues	5
Efficacy of Preventing Relapse Evaluated by a Multicenter Randomized Double-Blind Placebo-Controlled Withdrawal Study of Escitalopram in Japanese Adolescents with Major Depressive Disorder	5
Letter to the Editor: Aripiprazole-Induced Hypersexuality in an Autistic Child	5
Rosalind Franklin Society Proudly Announces the 2022 Award Recipient for Journal of Child and Adolescent Psychopharmacology	5
Pain in Tourette Syndrome: A Comprehensive Review	5
Pharmacokinetics, Safety, and Tolerability of Cariprazine in Pediatric Patients with Bipolar I Disorder or Schizophrenia	5
A Long-Term, Open-Label Safety and Tolerability Study of Lisdexamfetamine Dimesylate in Children Aged 4–5 Years with Attention-Deficit/Hyperactivity Disorder	5
Clinical Use of Clozapine Serum Level and Management of Adverse Effects in an Adolescent with Difficult to Treat Schizophrenia	5
From the Editor-in-Chief's Desk: Advances in Patient-Centered Treatment for Attention-Deficit/Hyperactivity Disorder	5
Correction to: A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder, by Strawn et al. J Child Adolesc Psychopha	5
Stimulant Patterns, Alone or with Other Psychotropic Classes, in Medicaid-Insured Youth Continuously Enrolled for 3–8 Years	5
Association Between Single-Dose and Longer Term Clinical Response to Stimulants in Attention-Deficit/Hyperactivity Disorder: A Systematic Review of Randomized Controlled Trials	5
Multivariable Prediction Modeling of Antidepressant Initiation in Unipolar Depressed Adolescents: A Secondary Analysis of the IMPACT Trial	5
Comparing Symptoms of Major Depression in Youth with Confirmed Versus Suspected Bipolar Disorder	5
Evaluation of the Psychometric Properties of the Persian Version of Children's Depression Inventory in Iranian Adolescents	5
Clonazepam Treatment of Adolescent Catatonia in A Setting of Lorazepam-Related Hypotension	5
Bowel and Bladder Dysfunction Is Associated with Psychiatric Comorbidities and Functional Impairment in Pediatric Obsessive-Compulsive Disorder	5
Factors Associated with Symptom Persistence in PANS: Part II—Presenting Features, Medical Comorbidities, and IVIG Treatment History	5
Correction to: The Importance of Second-Generation Antipsychotic-Related Weight Gain and Adherence Barriers in Youth with Bipolar Disorders: Patient, Parent, and Provider Perspectives, by Klein	4

The Psychosocial Environment as Therapeutic Context: Family-Centered Approaches to Adolescent Psychedelic Research	4
Relative Age Effect on Problematic Alcohol Use in Adolescents	4
Results from a Double-Blind, Randomized, Placebo-Controlled, Single-Dose, Crossover Trial of Lovastatin or Minocycline in Fragile X Syndrome	4
From the Editor-in-Chief's Desk	4
Analysis of Growth Velocity in Children with Attention-Deficit/Hyperactivity Disorder Treated for up to 12 Months with Serdexmethylphenidate/Dexmethylphenidate	4
Adherence to Clinical Guidelines for Dose Finding and Monitoring Methylphenidate Use: A Medical Record Audit in Child and Adolescent Mental Health Care and Pediatric Settings	4
Clinicians' Adherence to Guidelines When Initiating Methylphenidate Treatment	4
A Scoping Review of the Intersectionality of Autism and Intellectual and Developmental Disability with Social Inequity on Diagnosis and Treatment of Youth	4
Risk of Obesity Among Children Prescribed Atypical Antipsychotics for Six Months or More	4
A Randomized, Controlled Laboratory Classroom Study of Serdexmethylphenidate and d-Methylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder	4
From the Editor-in-Chief's Desk	4
From the Editor-in-Chief's Desk	4
Comorbidities in School-Age Children and Adolescents with Autism in an Ethnically Diverse Population: Brief Report	4
From the Editor-in-Chief’s Desk: Special Issue on the Psychopharmacology of Neurodevelopmental Disorders	4
Electronically Monitored Antidepressant Adherence in Adolescents with Anxiety Disorders: A Pilot Study	4
Safety and Efficacy of Brexpiprazole in the Treatment of Irritability Associated with Autism Spectrum Disorder: An 8-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial and 26-Week Open-	4
Trajectories and Predictors for the Development of Clinically Significant Weight Gain in Children and Adolescents Prescribed Second-Generation Antipsychotics	4
From the Editor-in-Chief's Desk	4
From the Editor-in-Chief's Desk	4
Efficacy and Safety of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study	4
Prevalence and Factors Affecting the Use of Antipsychotics and Antipsychotic Polypharmacy in a Child and Adolescent Psychiatry Inpatient Service	4
From the Editor-in-Chief's Desk	3
Letter: Food and Drug Administration Clearance of Transcranial Magnetic Stimulation for Adolescent Depression in the Absence of Data Supporting Efficacy	3
26-Week Open-Label Extension Study Evaluating the Safety and Tolerability of Flexible Doses of Oral Ziprasidone in Children and Adolescents with Bipolar I Disorder (Most Recent Episode Manic)	3
A Predictive Biomarker Model Using Quantitative Electroencephalography in Adolescent Major Depressive Disorder	3
High-Frequency Utilization of the Outpatient Messaging System in a Specialized Outpatient Catatonia Clinic for Individuals with Autism Spectrum Disorder	3
From the Editor-in-Chief's Desk	3
Letter to the Editor: Delayed Fibrosis and Late Course Magnetic Resonance Imaging Findings in Clozapine-Induced Myocarditis in an Adolescent	3
Longitudinal Patterns of Community-Based Treatment Utilization Among Ethnically and Racially Diverse Adolescents with Attention-Deficit/Hyperactivity Disorder	3
Prevalence and Correlates of Eating Disorder Symptoms in Adolescents with Bipolar I Disorder	3
Letter: Seventeen-Year-Old Develops Neuroleptic Malignant Syndrome after Brief Low-Dose Exposure to Aripiprazole: A Case Report	3
Stimulants Concomitant with Other Psychotropic Classes: A Competing Risk Analysis in Medicaid-Insured Youth	3
Psychotropic Medication Prescription Patterns in Down Syndrome in a Large Pediatric Specialty Clinic	3
Vineland-3 Growth Scale Values: Psychometric Properties for Clinical Trial Readiness in SCN2A	3
Guanfacine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents with Down Syndrome: A Retrospective Chart Review	3
Growth Trajectories in Stimulant Treated Children and Adolescents: A Qualitative Review of the Literature from Comprehensive Datasets and Registries	3
Letter to the Editor: Antidepressant and Antisuicidal Effects of Esketamine in Adolescents with Major Depressive Disorder and Suicidal Ideation: A Case Series	3
A Discrepancy in the Reports on Life Events Between Parents and Their Depressed Children Is Associated with Lower Responsiveness to SSRI Treatment	3
Pharmacogenetics and Oxcarbazepine in Children and Adolescents: Beyond HLA-B*15:02	3
Letter: Extended-Release Lorazepam as a Safe and Effective Option for Treating Catatonia in an Individual with Down Syndrome	3
A Meta-Analysis of Antipsychotic-Induced Hypo- and Hyperprolactinemia in Children and Adolescents	3
A Short-Term Group Telehealth Cognitive Behavioral Therapy Intervention for Youth with Autism and Anxiety: A Pilot Study	3
Viloxazine Extended-Release Administered With Psychostimulants in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Phase 4, Open-Label Trial	3
Examining Antidepressant Side Effect Burden in Youth: The FIBSER-C Scale in the Texas Youth Depression and Suicide Research Network Study	3
Letter: Paradoxical Sedation on Methylphenidate in a Child with Attention-Deficit/Hyperactivity Disorder	2
Pediatric Psychotropic Polypharmacy: An Evaluation of the Correlates and Prevalence Across Assessment Cycles in the National Health and Nutrition Examination Survey	2
Letter to the Editor: A Positive Tetrahydrocannabinol on Urine Screen After Cannabidiol Oil Use in an Adolescent	2
Children's Relative Age and Medicine Treatment for Attention-Deficit/Hyperactivity Disorder Across Australian Jurisdictions with Different School Enrolment Policies	2
Exploring Risk Factors for Adverse Reactions in Children with an Acute Psychotic Episode Using the Global Trigger Tool: Does Age Matter?	2
National Trends in Pediatric Obsessive compulsive disorder Management: Insights from a Retrospective Cohort Study	2
Clozapine Treatment for Aggressive Behaviors in Youths with Neurodevelopmental Disorders	2
Letter: Can Epileptic Seizures Explain Hyperactive Catatonia in Patients with Autism and Intellectual Disability?	2
C-Reactive Protein Does Not Predict Future Depression Onset in Adolescents: Preliminary Findings from a Longitudinal Study	2
Rett Syndrome Behaviour Questionnaire: Variability of Scores and Related Factors	2
From the Editor-in-Chief’s Desk: Psychedelic Therapeutics—Something Old and Something New	2
Predictors of Placebo Response in the Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors	2
Cost-Effectiveness and Cost Utility of Treatment of Attention-Deficit/Hyperactivity Disorder: A Systematic Review	2
Acknowledgment of Reviewers 2024	2
Suicide, Stimulants, and Selective Serotonin Reuptake Inhibitors: A Retrospective Chart Review	2
Long-Acting Injectable Antipsychotic Medication Use in Youth: A Systematic Review of the Literature Along with MedWatch Safety Data and Prescriber Attitudes	2
From the Editor-in-Chief's Desk	2
The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression	2
Diagnosis of Autism in School Age and Adolescence in an Ethnically Diverse Population	2
Medication Prescribing Patterns at a Youth Mental Health Service: A Single Center Retrospective Cross-sectional Study	2
Re: “Effects of Long-Term Sertraline Use on Pediatric Growth and Development: The Sertraline Pediatric Registry for The Evaluation of Safety (SPRITES)” by Kolitsopoulos et al.	2
Letter: Agitation Management in a 5-Year-Old Boy with X Chromosome-Linked Monoamine Oxidase-A and Monoamine Oxidase-B Deficiency	2
Severe Early-Onset Conduct Disorder and Pervasive Violence in a Patient with Comorbid Neurodevelopmental Disorders	2
Letter: A Rare Case of Dose-Dependent Priapism in a Child with Autism Treated with Aripiprazole and Risperidone	2
Adherence Rates and Barriers to Second-Generation Antipsychotic Medication Use in Youth with Bipolar Spectrum Disorders Who Have Overweight/Obesity	2
Pharmacotherapy May Attenuate the Risk of Child Abuse in Attention-Deficit/Hyperactivity Disorder from the Real-World Evidence	2
Short- and Long-Term Outcomes of Suboptimal Medication Adherence in Adolescents with Attention-Deficit/Hyperactivity Disorder: A Systematic Literature Review	2
From the Editors Desk: From Pediatric Infection Triggered Autoimmune Neuropsychiatric Disorders to Long COVID—Progress, Quandaries, and Parallels	2
Efficacy of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder: Effect Size Across the Day	2
Not Too Rare to Matter: The Incidence of Neuroleptic Malignant Syndrome in Children and Adolescents Treated with Antipsychotics	2
Selective Serotonin Reuptake Inhibitors and Hydroxyzine in the Treatment of Avoidant/Restrictive Food Intake Disorder in Children and Adolescents: Rationale and Evidence	2
Switch to Lisdexamfetamine in the Treatment of Attention-Deficit Disorder at a Psychiatric Outpatient Clinic for School-Aged Children: A Danish Cohort Study	2
Efficacy, Safety, and Tolerability of Flexibly Dosed Ziprasidone in Children and Adolescents with Mania in Bipolar I Disorder: A Randomized Placebo-Controlled Replication Study	2
Treatment of Adolescent Depression: Comparison of Psychiatric and Pediatric Settings at an Academic Medical Center Using the VitalSign6 Application	2
Association of Lithium and Second-Generation Antipsychotics with Neurocognition in Youth with Bipolar Disorder	2
Understanding and Managing New Onset Homicidal Ideation in an Adolescent with Depression	2

Letter: Exploring the Relationship Between Smartphone Addiction, Psychological Distress, Stress, and Self-Esteem Among Moroccan High School Students: A Regression Equation Modeling Study	2
Predictors and Moderators of Treatment Outcomes for Anxious Children Randomized to Computer-Assisted Cognitive Behavioral Therapy or Standard Community Care	2
Preliminary Observations of Resting-State Magnetoencephalography in Nonmedicated Children with Obsessive-Compulsive Disorder	2
Safety and Efficacy of Levomilnacipran Extended Release in Pediatric Patients Aged 7–17 Years with Major Depressive Disorder: Results of Two Phase 3, Randomized, Double-Blind Studies	2
Clozapine for Management of Childhood and Adolescent-Onset Schizophrenia: A Systematic Review and Meta-Analysis	2
A 16-Year-Old Male with Autism Spectrum Disorder, Psychosis, and Refusal to Accept Any Oral Medication: A Case Report and Use of Long-Acting Injectable Aripiprazole Lauroxil	2
Comparison of Fidgeting in Adolescents with Attention-Deficit/Hyperactivity Disorder Between Before and After Stimulant Medication Intake	2
A Retrospective Examination of the Impact of Pharmacotherapy on Parent–Child Interaction Therapy	2
Guanfacine for the Treatment of Attention-Deficit Hyperactivity Disorder: An Updated Systematic Review and Meta-Analysis	2
Rosalind Franklin Society Proudly Announces the 2024 Award Recipient for Journal of Child and Adolescent Psychopharmacology	2
Co-Occurring Anxiety in Youth with Tic Disorders: A Review	2
Comparison of Psychiatric Readmission Rates for Child and Adolescent Patients on Long-Acting Injectable Antipsychotics Versus Oral Antipsychotics: A Mirror Study	2
Re: “A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder” by Strawn et al.—Concerning Harm–Benefit Ratio in a Recent Tria	2
The Mental Health Toll of the COVID-19 Pandemic on Adolescents Receiving Inpatient Psychiatric Treatment	2